You are here

Article Text

Article menu
Download PDFPDF
Letter
Central serous chorioretinopathy after inhaled steroid use for post-mycoplasmal bronchospasm
  1. B Fardin,
  2. D J Weissgold
  1. Department of Ophthalmology, College of Medicine, University of Vermont, Burlington, Vermont, USA
  1. Correspondence to: David J Weissgold, MD, Ophthalmology, UVM/FAHC, 1 S Prospect Street, Burlington, VT 05401, USA; david.weissgold{at}vtmednet.org

https://doi.org/10.1136/bjo.86.9.1065

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Central serous chorioretinopathy (CSR) is an uncommon cause of central visual loss, metamorphopsia, and dyschromatopsia, generally involving submacular and/or subretinal pigment epithelial (RPE) fluid blisters. While most cases of CSR are idiopathic, several associated risk factors have been implicated, such as so called type A personality, emotional stress, and male sex.1 Systemic steroid use has long been known to be associated with CSR.2 This case report demonstrates the development of CSR secondary to inhaled steroid use specifically for the management of post-mycoplasmal bronchospasm.

    Case report

    We evaluated a 40 year old white woman for complaints of metamorphopsia and decreased visual acuity on the left side for approximately a 2 month period. She denied previous similar episodes in either eye. Four months earlier, treatment for bronchospasm following mycoplasmal pneumonia had been initiated …

    View Full Text